SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?


To: Easy Mark who wrote (350)4/4/1998 3:49:00 PM
From: Greed Is Good  Respond to of 1510
 
I just received the most recent Individual Investor magazine (May 98) and it has a small follow up article on IMNR from when it was originally recommended in 4/97 @ $6.75/sh. Basically, it says IMNR is their typical Bio-tech company with no earnings projected for 1998, but with Remune and RA drugs on the horizon. It finished with "if the FDA approves Remune, the stock could shoot to $40 from the recent $9.88".